Welcome to our dedicated page for Organogenesis Hldgs news (Ticker: ORGO), a resource for investors and traders seeking the latest updates and insights on Organogenesis Hldgs stock.
Organogenesis Holdings Inc. develops, manufactures and sells regenerative medicine and tissue-innovation products for the Advanced Wound Care and Surgical & Sports Medicine markets. News about the company commonly covers product revenue by those markets, gross margin and profitability trends, and corporate updates tied to its Nasdaq-listed Class A common stock.
Company updates also focus on clinical and regulatory activity across its portfolio. Recurring subjects include PuraPly AM clinical evidence in diabetic foot ulcers, ReNu as a cryopreserved amniotic suspension allograft for symptomatic knee osteoarthritis, FDA interactions, Biologics License Application activity, and coverage or payment developments affecting skin-substitute and wound-care products.
Organogenesis (Nasdaq: ORGO) reported preliminary Q3 2020 results with net revenue projected between $99.0 million and $100.0 million, marking a 54% to 56% increase from $64.3 million in Q3 2019. Advanced Wound Care products contributed $88.5 million to $89.3 million, up 63% to 64%, while Surgical & Sports Medicine products generated $10.5 million to $10.7 million, a 5% to 7% rise. The company's updated FY 2020 guidance estimates net revenue of $311 million to $314 million, with anticipated positive GAAP net income and adjusted EBITDA.
Organogenesis Holdings Inc. (Nasdaq: ORGO) announced a change in its presentation schedule for the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit. The company will now present on September 21, 2020, at 2:30 p.m. Eastern Time, instead of the previously scheduled time of September 22, 2020, at 4:10 p.m. Eastern Time. A live audio webcast of the presentation will be available on the company’s website, with a replay accessible for approximately 30 days post-event. Organogenesis specializes in regenerative medicine, providing solutions for advanced wound care and surgical needs.
Organogenesis Holdings, focused on regenerative medicine, will participate in two investor conferences. Management will engage in a fireside chat at the Morgan Stanley 18th Annual Global Healthcare Conference on September 16 at 5:00 p.m. ET, followed by another at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22 at 4:10 p.m. ET. Live audio webcasts will be available on their Investor Relations webpage, with replays accessible for 30 days.
Organogenesis Holdings Inc. (Nasdaq: ORGO) announced the resignation of CFO Timothy M. Cunningham effective August 18, 2020. His departure was not due to disputes or financial issues. Henry Hagopian, previously Vice President of Finance, has stepped in as interim CFO while a national search for a permanent replacement begins. CEO Gary S. Gillheeney acknowledged Cunningham's role in the company's progress and public transition. Hagopian brings extensive financial experience, including previous roles at CIRCOR International and Lucent Technologies.
Organogenesis Holdings Inc. (ORGO) reported a net revenue of $69 million for Q2 2020, an increase of 6% year-over-year. Revenue from Advanced Wound Care products rose 8% to $59.7 million, while Surgical & Sports Medicine products declined by 5% to $9.2 million. The net loss improved to $5.2 million from $9.6 million in Q2 2019. Adjusted EBITDA was $274,000, up from a loss of $4.8 million. The company reinstated its 2020 revenue guidance for 5%-6% growth, reflecting strong operational fundamentals despite the COVID-19 pandemic.
Organogenesis Holdings (Nasdaq: ORGO) announces participation as a Platinum Sponsor at the 2020 Symposium on Advanced Wound Care (SAWC) Virtual Experience from July 24-26. The company's advanced wound care research, including products like Apligraf and Dermagraft, will be showcased. Highlights include an Innovation Theater event and multiple virtual Private Networking Suites for attendees to engage with experts. Key poster presentations cover studies on various wound treatments, including living cellular constructs and collagen dressings for venous leg ulcers.
Organogenesis Holdings Inc. (Nasdaq: ORGO) has scheduled its second quarter 2020 financial results announcement for August 10, 2020, after market close. A conference call will follow at 5:00 p.m. ET, providing updates and a question and answer session. Investors can join by dialing 866-795-3142 or via a live webcast on the company’s investor relations website. A replay will be available for two weeks. Organogenesis specializes in regenerative medicine products for Advanced Wound Care and Surgical markets.
Organogenesis Holdings Inc. (Nasdaq: ORGO) reported net revenue of $61.7 million for Q1 2020, an increase of 8% from $57.1 million in Q1 2019. Advanced Wound Care products generated $51.3 million, up 7%, while Surgical & Sports Medicine products increased 13% to $10.4 million. Despite revenue growth, the company recorded a net loss of $16.3 million, compared to a $15.7 million loss a year earlier. The company withdrew its fiscal year 2020 revenue guidance due to uncertainty from the COVID-19 pandemic, prioritizing cost-saving measures.